Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDOV-SAFE + toripalimab + fruquintinib
- Development stage
- Phase 1
- Lead developer
- Peking University
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IIC1-Peking University-digestive system tumor refers to a specific treatment cohort (Cohort IIC1) within a Phase I clinical trial (NCT06380309) evaluating the combination of IDOV-SAFE, toripalimab, and fruquintinib. IDOV-SAFE is an investigational oncolytic vaccinia virus designed to selectively replicate in and destroy cancer cells while stimulating a systemic anti-tumor immune response. Toripalimab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to restore T-cell activity. Fruquintinib is a highly selective small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), which inhibits tumor angiogenesis. This triple combination is being investigated for advanced malignant solid tumors, particularly digestive system cancers such as microsatellite stable (MSS) colorectal cancer, gastric cancer, and esophageal squamous cell carcinoma, in patients who have failed standard therapies.
- Brand names
- Tuoyi
- Other names
- IDOV-SAFE + toripalimab + fruquintinib combination therapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on IDOV-SAFE + toripalimab + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDOV-SAFE + toripalimab + fruquintinib.